As gene therapy progresses, you'll see other players get involved..The problem for those entities, catching up is extremely difficult..Once you are embedded into a clinical trial program, it becomes very difficult to switch. I believe you have to go through the FDA process again.. Don't quote me, but I do believe.. CYRX has locked all the major gene players down already.. So if I was to speculate, two things will happen.. By the time another competitor gets even remotely close, most of us have sold and moved on with our lives, or we get bought out..
News 
Market Data 
Discover 
AI
